AVXL — Anavex Life Sciences Share News
0.000.00%
Last trade - 00:00- $106.60m
- -$11.72m
Anavex Life Sciences Corp expected to post a loss of 14 cents a share - Earnings Preview
Brief: Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial Of Anavex®3-71 In Schizophrenia
U.S. STOCKS ON THE MOVE-Coherus, Moderna
U.S. STOCKS ON THE MOVE-Rivian, Terran Orbital, Longboard Pharmaceuticals
U.S. STOCKS ON THE MOVE-Apple, NGM Biopharmaceuticals, Voyager Therapeutics
Anavex down after neurological disorder drug fails to meet one of the main goals
Brief: Anavex Announces First Entire Clinical Gene Pathway Data Of Anavex®2-73 From Avatar Study In Patients With Rett Syndrome
U.S. STOCKS ON THE MOVE-Rockwell Automation, Crinetics Pharmaceuticals, TransUnion
Anavex up on plans to seek regulatory approval for lead drug in Europe
Brief: Anavex Received Agreement From The Committee For Medicinal Products For Human Use (CHMP) For The Submission Of A Marketing Authorisation Application Of Oral Blarcamesine For Alzheimer’S Disease
Brief: Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results And Provides Business Update
Anavex Life Sciences Corp reports results for the quarter ended in September - Earnings Summary
Anavex Life Sciences Corp expected to post a loss of 15 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Virgin Galactic, Boeing, Zscaler
Newscasts - Trading at Noon: Wall Street rises, but Nvidia slips and oil tumbles as OPEC+ meeting delayed
U.S. STOCKS ON THE MOVE-Cruise operators, Freeline, GoodRx
Anavex rises on US patent for insomnia, anxiety treatment
Brief: Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine for Treatment of Insomnia or Anxiety
Brief: Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency